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Edited by Vladimir SkulachevAbstract Peroxiredoxins are an ubiquitous family of peroxi-
dases widely distributed among prokaryotes and eukaryotes.
Peroxiredoxin 5, which is the last discovered mammalian
member, was previously shown to reduce peroxides with the
use of reducing equivalents derived from thioredoxin. We report
here that human peroxiredoxin 5 is also a peroxynitrite
reductase. Analysis of peroxiredoxin 5 mutants, in which each
of the cysteine residues was mutated, suggests that the nucleo-
philic attack on the O–O bond of peroxynitrite is performed by
the N-terminal peroxidatic Cys47. Moreover, with the use of
pulse radiolysis, we show that human peroxiredoxin 5 reduces
peroxynitrite with an unequalled high rate constant of
(7% 3) 107 M1 s1.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Along the mitochondrial electron-transfer chain, the reac-
tion between nitrogen monoxide and superoxide is highly fa-
vorable and produces peroxynitrite [1], which can not only
damage mitochondrial components but also the cell by pro-
moting lipid peroxidation as well as DNA and protein oxi-
dation leading to cell death [2]. Considering the implication of
peroxynitrite in numerous pathological processes [3–5], it is
surprising that defense mechanisms against this toxic nit-
rooxidant are still poorly understood.
Peroxiredoxins (PRDXs) have been identiﬁed as a large
family of peroxidases able to reduce H2O2 and alkyl hydro-
peroxides [6–10]. These enzymes are widely distributed among
prokaryotes and eukaryotes [9]. It is now becoming clear that
PRDXs are part of the enzymatic antioxidant system, collab-
orating in cells with well-characterized catalase, superoxide* Corresponding author. Fax: +32-10-47-35-15.
E-mail address: knoops@bani.ucl.ac.be (B. Knoops).
Abbreviations: AhpC, alkyl hydroperoxide reductase subunit C; DHR
123, dihydrorhodamine 123; DTT, dithiothreitol; GPX, glutathione
peroxidase; Mn-SOD, manganese-superoxide dismutase; ONOO/
ONOOH, peroxynitrite; ONO/ONOH, nitrite; PBS, phosphate-buf-
fered saline; PRDX, peroxiredoxin; RDH 123, rhodamine 123; TXN,
thioredoxin; TXNRD, thioredoxin reductase
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mammals, there are six PRDXs encoded by six distinct genes
[10,12]. PRDX5, also named PrxV, AOEB166, PMP20 or
ACR1, is the last discovered mammalian PRDX [12–16].
Human PRDX5 can be intracellularly localized to mitochon-
dria, peroxisomes, the cytosol and, to a lesser extent, the nu-
cleus [16]. Mitochondrial localization of PRDX5 seems to be
essential as peptidic sequence alignment of the human protein
with its orthologues in other animal species from invertebrates
to vertebrates reveals the conservation of a predicted mito-
chondrial targeting presequence (Fig. 1).
Recently, alkyl hydroperoxide reductase subunit C (AhpC),
a bacterial PRDX homologue of human PRDX5, was reported
to possess a peroxynitrite reductase activity [17]. In the view of
this, we hypothesized that human PRDX5 could also aﬀord
protection against peroxynitrite.1 Results presented here show
that PRDX5 is indeed a peroxynitrite reductase and that it
could play a major protective role in animal cells against this
toxic nitrooxidant.2. Materials and methods
2.1. Expression and puriﬁcation of recombinant proteins
Human PRDX5 (GenBank Accession No. NM_012094) [13] and
human thioredoxin 2 (TXN2, GenBank Accession No. U78678) [18]
were expressed without their mitochondrial presequence in Escherichia
coli strain M15 (pRep4) as 6·His-tagged proteins using pQE-30 ex-
pression vector (Qiagen) and puriﬁed as described previously [15,16].
Human PRDX5 mutants, C47S, C72S and C151S (amino acid num-
bering refers to mature protein, see Fig. 1), were generated by PCR-
mediated site-directed mutagenesis using complementary primers
containing base mismatch that converted the codon for Cys to a codon
for Ser. Lactate dehydrogenase (LDH) from Streptococcus thermo-
philus was expressed in E. coli strain TOP10 (Invitrogen) as a 6·His-
tagged protein using pBAD/His expression vector (Invitrogen) and
puriﬁed as for PRDX5 and TXN2.
2.2. Assay of peroxynitrite-mediated oxidation of dihydrorhodamine 123
(DHR 123)
Peroxynitrite-mediated oxidation of DHR 123 was followed as de-
scribed [19] using a ﬂuoroscan Ascent FL spectrophotometer (Lab-
systems) with excitation and emission wavelengths of 515 and 555 mn,
respectively. Peroxynitrite was synthesized as described by Koppenol
et al. [20]. Peroxynitrite (600 nM) was added to 750 nM DHR 123
(Molecular Probes) and to diﬀerent concentrations of reduced or ox-
idized PRDX5. DHR 123 was dissolved in phosphate buﬀer, 100 mM
(pH 7.4), chelexed and supplemented with 100 lM diethylenetriamine1 In the present work, we use the term peroxynitrite for peroxynitrite
anion and peroxynitrous acid without any distinction.
blished by Elsevier B.V. All rights reserved.
Fig. 1. Amino acid sequence alignment of human PRDX5 and orthologues in vertebrates and invertebrates. The alignment was generated by
CLUSTAL W 1.7 [40]. Residues conserved between mature human PRDX5 and its orthologues are highlighted in dark gray and conservative
residues are highlighted in light gray. Conﬁrmed (Homo sapiens) and predicted mitochondrial presequences are underlined. Mitochondrial prese-
quences were predicted with TargetV1.0 (http://www.cbs.dtu.dk/services/TargetP/; [41]). Alignment of cysteines corresponding to human peroxydatic
Cys47 (*), Cys72 (r) and resolving Cys151 ðdÞ is indicated. GenBank Accession Nos. are NM_012094 (Homo sapiens), NM_012021 (Mus musculus),
NM_174749 (Bos taurus), BJ053922 (Xenopus laevis), CN508467 (Danio rerio), AF498232 (Branchiostoma belcheri), and NM_176512 (Drosophila
melanogaster).
162 M. Dubuisson et al. / FEBS Letters 571 (2004) 161–165pentaacetic acid. Reduced PRDX5 was obtained after incubation for
30 min at 37 C with 10 mM dithiothreitol (DTT) in phosphate-buf-
fered saline (PBS) and then passed through a PD10 desalting column
(Amersham) to remove DTT. Oxidized PRDX5 was prepared by the
addition of 10 mM H2O2 during 30 min at 37 C in PBS and passed
through a PD10 column.
2.3. TXN-dependent peroxidase activity of PRDX5
Peroxidase reaction was performed as previously described [21] with
minor modiﬁcations. Brieﬂy, peroxidase reaction was performed in a
75 ll reaction mixture containing 250 lM NADPH (Sigma), 0.2 lM
recombinant rat thioredoxin reductase 1 (TXNRD1, IMCO), 2.2 lM
TXN2 and 1.5 lM PRDX5 in PBS (pH 7.4). The reaction was initiated
by the addition of 0.5 mMH2O2. The initial rate of NADPH oxidation
was monitored by measurement of absorbance decrease at 340 nm in
the presence of PRDX5 at 37 C.
2.4. Measurement of nitrite and nitrate
Nitrite and nitrate concentrations were measured by anion chro-
matography with conductometric detection as described earlier [22].
2.5. Stopped-ﬂow spectrophotometry
The reaction was initiated by mixing a peroxynitrite solution (4 lM
ﬁnal concentration) in 0.01 M sodium hydroxide with protein solubi-
lized in 0.14 M PBS (pH 7.4) with a ratio of 1:11. Proteins were ﬁrst
reduced or oxidized with 10 mM DTT or H2O2 and were subsequently
passed through a PD10 desalting column. Stopped-ﬂow observations
were carried out at 300 nm (25 C) with an Applied Photophysics SX
17 MV device.
2.6. Pulse radiolysis
Experiments were carried out with Febetron 705 2 MeV accelerator
(Titan Corp.) with a pulse width of 50 ns and doses between 20 and 60
Gy. A 75 W Xe-Arc lamp was used as light source. Irradiations were
carried out in a 1 cm Suprasil Quartz cell (Hellma). Peroxynitrite was
produced in situ with formate and nitrite as previously described [23],
except that the concentration of formate was decreased to a ﬁnal
concentration of 10 mM. Nitrite concentration was 2 mM. pH was setto 7.8. Protein was used at a ﬁnal concentration of 50 lM. Peroxyni-
trite was followed at 300 nm. As the energy of the 2 MeV electrons is
absorbed by water, there was no radiation damage to the solutes.3. Results
3.1. Human PRDX5 protects against DHR 123 oxidation
caused by peroxynitrite
Reduced wild-type recombinant PRDX5 caused a pro-
nounced inhibition of DHR 123 oxidation into rhodamine 123
(RDH123) (Fig. 2A).Whenwild-typePRDX5wasﬁrst oxidized
by H2O2, this inhibition disappeared. As a negative control,
reduced 6·His-LDH had no protective eﬀect (Fig. 2A).
3.2. Cys47 of PRDX5 is necessary for protection against DHR
123 oxidation caused by peroxynitrite
In order to investigate the role of the three cysteines of
PRDX5, we tested the inhibition of DHR 123 oxidation by
peroxynitrite conferred by the three PRDX5 mutants: C47S,
C72S and C151S. PRDX5 mutants were reduced or oxidized.
Among the reduced mutants, only C72S and C151S retained
their activity, which was similar to that of the reduced wild-
type enzyme (Fig. 2B). Reduced C47S mutant was totally in-
eﬀective. No protection was detected with any of the oxidized
mutants. These results show that Cys47 is essential for pro-
tection by PRDX5 against peroxynitrite-mediated oxidation of
DHR 123 and that the reduced status of Cys47 is also required.
3.3. PRDX5 is a peroxynitrite reductase
We then investigated whether PRDX5 oxidized by peroxy-
nitrite could be reduced enzymatically by the TXN system
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Fig. 3. (A) TXN-dependent peroxidase activity of wild-type PRDX5
(wt) and mutants after oxidation by peroxynitrite. Wild-type PRDX5
or mutants (20 lM) were pretreated either with peroxynitrite (40 lM)
(gray columns) or buﬀer alone (black columns) during 30 min at 37 C,
after which they were passed through a desalting column and TXN-
dependent peroxidase activity was measured in the presence of
NADPH, TXNRD1, TXN2 and H2O2 (meanS.E.M., n ¼ 3). (B)
Measurement of nitrite and nitrate levels after peroxynitrite degrada-
tion, alone or in the presence of either reduced wild-type PRDX5 (wt)
or C47S mutant. Results are expressed in percents of the total content
of nitrite and nitrate in the reaction mixture (black, nitrate; gray,
nitrite; meanS.E.M., n ¼ 3).
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Fig. 2. (A) Protection by diﬀerent concentrations of PRDX5 against
DHR 123 oxidation into RDH 123 caused by peroxynitrite. Peroxy-
nitrite was added to wild-type PRDX5 (reduced, closed circles; oxi-
dized, closed squares) or reduced LDH (open triangles) (meanS.E.M.,
n ¼ 3). (B) Protection by PRDX5 mutants against DHR 123 oxidation
caused by peroxynitrite. Mutants C47S (reduced, open triangles; oxi-
dized, closed circles), C72S (reduced, open diamonds; oxidized, closed
triangles) or C151S (reduced, closed squares; oxidized, open squares)
were added at diﬀerent concentrations to the reaction mixture. Peroxy-
nitrite was added to initiate the reaction (mean S.E.M., n ¼ 3).
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reversible as required for peroxynitrite reductase activity. To
demonstrate this, 20 lM wild-type PRDX5 as well as C47S,
C72S and C151S mutants were ﬁrst treated with 40 lM per-
oxynitrite. Reductase activity of PRDX5 oxidized by peroxy-
nitrite was then measured with the TXN system containing
NADPH, TXNRD1, TXN2 and H2O2 (Fig. 3A). Results
showed that wild-type PRDX5 as well as C72S mutant oxi-
dized by peroxynitrite can be reduced by the TXN system and
that this oxidation does not alter their functionality. As ex-
pected from previous biochemical analyses [14], C47S and
C151S mutants were devoid of TXN-dependent peroxidase
activity. We then measured the formation of nitrite and ni-
trate from peroxynitrite decay in the presence or absence of
either reduced wild-type PRDX5 or C47S mutant. As the
spontaneous decay of peroxynitrite generates mostly nitrate at
physiological pH [22], the increase in nitrite in the presence of
protein is a measure of peroxynitrite reduction. As shown in
Fig. 3B, the spontaneous decomposition of peroxynitrite
yields 80% nitrate and 20% nitrite. The addition of reduced
wild-type PRDX5 reversed that ratio as the proportion of
nitrate and nitrite was then 29% and 71%, respectively, indi-cating a successful competition with the spontaneous isom-
erization of peroxynitrite to nitrate.
3.4. PRDX5 reacts with peroxynitrite with a very high rate
constant
Initially, we used stopped-ﬂow spectrophotometry to study
the kinetics of reaction of PRDX5 with peroxynitrite. Results
showed that only reduced wild-type PRDX5 reacted rapidly
and completely with peroxynitrite (data not shown). The dis-
appearance of peroxynitrite could not be recorded because all
peroxynitrite had been consumed during the mixing time of 1.5
ms. As expected, the reduced or oxidized C47S mutant did not
signiﬁcantly aﬀect the rate of peroxynitrite decay. We then
used pulse radiolysis in order to observe the fast kinetics of the
reaction of wild-type PRDX5 with peroxynitrite. When the
protein was added, all peroxynitrite disappeared extremely
rapidly (Fig. 4). From eight replicates of peroxynitrite decay
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Fig. 5. Proposed catalytic mechanism of PRDX5 in the reduction of
peroxynitrite to nitrite.
Fig. 4. Formation of peroxynitrite fromO2 and
NOby pulse radiolysis
in the presence (dots) and absence (line) of 50 lM reduced wild-type
PRDX5. The traces were recorded at 300 nm. Air saturated solutions of
2 mM nitrite and 10 mM formate at pH 7.8 were irradiated.
164 M. Dubuisson et al. / FEBS Letters 571 (2004) 161–165kinetics, we calculated that the rate constant of reduced wild-
type PRDX5 with peroxynitrite is (7 3) 107 M1 s1.4. Discussion
We demonstrate here that human PRDX5 reduces peroxy-
nitrite extremely rapidly and acts as a peroxynitrite reductase.
The obligatory presence of reduced Cys47 was established for
this protein to reduce peroxynitrite, suggesting that PRDX5
reaction towards peroxynitrite is similar to the one previously
proposed for AhpC and bovine PRDX6 [17,24]. Cys47 may be
oxidized to a sulfenic acid after a nucleophilic attack on the O–
O bond of peroxynitrite, with the concomitant formation of
nitrite. In the case of PRDX5, following the peroxidatic
pathway, the cysteine sulfenic acid (Cys47-SOH) would react
with resolving Cys151 (Cys151-SH) to form an intramolecular
disulﬁde intermediate, which could then be reduced by a
physiological electron donor such as cytosolic TXN1 or mi-
tochondrial TXN2 (Fig. 5). Accordingly, preincubation ex-
periment of PRDX5 with peroxynitrite and assay for
peroxidatic activity with the TXN system shows that Cys47
oxidized by peroxynitrite and subsequent intramolecular di-
sulﬁde intermediate can indeed be reduced by the TXN system,
including mitochondrial TXN2, demonstrating that this reac-
tion is catalytic and that the enzyme therefore exhibits true
peroxynitrite reductase activity. This peroxynitrite reductase
activity is further conﬁrmed by the measurements of the ratio
of nitrite and nitrate formed in the presence of reduced
PRDX5.
The rate constant of PRDX5 towards peroxynitrite,
(7 3) 107 M1 s1, is remarkably high. This rate constant
is at least two times higher than that of peroxynitrite
with Mn(III) 5,10,15,20-tetrakis(N-methylpyridyl)porphyrin
(1.9 107 M1 s1) [25], 20 times that with ebselen (2-phenyl-
1,2-benzisoselenazol-3(2H)-one, 2 · 106 M1 s1) [26], and 5
times that with reduced glutathione peroxidase 1 (GPX1,
8 · 106 M1 s1) [27]. Moreover, it is at least 25 times higher
than that reported for PRDX5 bacterial homologue, AhpC
(1.5 · 106 M1 s1) [17]. Even if cellular concentration and
turnover of PRDX5 must be considered, this high rate con-stant allows one to speculate that PRDX5 at the micromolar
concentration level competes eﬀectively for peroxynitrite with
carbon dioxide [28] at a physiological concentration of 1 mM.
A physiological protective role against peroxynitrite is there-
fore conceivable and is further supported by in vivo data,
suggesting that PRDX5 could protect from reactive nitrogen
species generated in alcohol-treated Xenopus embryos [29].
Similarly, as reported recently, mitochondrial PRDX3 could
also function in vivo as a protective peroxynitrite reductase
[30].
The lack of inactivation of PRDX5 catalytic activity by
peroxynitrite in our experimental conditions underlines even
more the ﬁne adaptation of this enzyme to react with peroxy-
nitrite. Many proteins or enzymes are indeed inactivated by
peroxynitrite. Mitochondrial manganese-superoxide dismutase
(Mn-SOD) is inactivated by nitration of its Tyr34 when ex-
posed to peroxynitrite [31]. Peroxynitrite also inactivates
GPX1 [32,33]. Interestingly, there is no Tyr residue in mature
human PRDX5 (Fig. 1). This could explain its lower suscep-
tibility to deleterious peroxynitrite attacks and may confer an
advantage of PRDX5 over other candidate peroxynitrite re-
ductase enzymes in mammalian cells such as GPX1 [34],
PRDX3 [30] and PRDX6 [24]. This absence of tyrosines in
PRDX5 could be a characteristic acquired later during evo-
lution, at least in mammals, as the bacterial AhpC is prone to
nitration of its tyrosines by peroxynitrite [17].
Recently, diﬀerent PRDXs were shown to be endowed with
peroxynitrite reductase activity, such as the yeast peroxire-
doxin Ttsa2p [35], the mammalian PRDX6 [24] and the bac-
terial AhpC [17,36]. However, it has also been demonstrated
that peroxynitrite reductase activity could not be generalized
to all PRDXs as bacterial Tpx or Bcp was not active to de-
toxify peroxynitrite [37].
Although PRDX5 has been detected in the peroxisomes, in
the cytosol and in the nucleus of mammalian cells, it appeared
that in many cell types, PRDX5 is primarily addressed to
mitochondria [13,14,38,39]. This mitochondrial localization,
which appears to be highly conserved throughout evolution,
probably reﬂects the physiological protective role of PRDX5
in these organelles, which are major sources and targets for
oxidative or nitrosative injuries. The peroxynitrite reductase
activity of PRDX5 could have important implications for the
understanding of mitochondrial protective mechanisms
against peroxynitrite-mediated damages in animal cells.
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